Brief: Lyell Immunopharma Says Impt-314 Receives Fast Track Designation From FDA
10/12/2024 02:02
Dec 9 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL PRESENTS POSITIVE INITIAL CLINICAL DATA FROM THE
PHASE 1-2
CLINICAL TRIAL OF IMPT-314 FOR THE TREATMENT OF B-CELL LYMPHOMA
AT THE 2024 ASH ANNUAL MEETING
* LYELL IMMUNOPHARMA INC - IMPT-314 RECEIVES FAST TRACK
DESIGNATION FROM FDA
Source text: ID:nGNX3ZDRRq
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma